WILMINGTON, Del., March 26, 2018 -- Navient Foundation, the company-sponsored philanthropic fund, announced a $7,500 grant to support Duffy’s Hope annual cross-country college tour. The nonprofit encourages Delaware’s at-risk youth to learn outside of the classroom.
|
|||||
“Thanks to Navient’s support, we’ve made a difference in the lives of several students from the city of Wilmington and surrounding areas,” said Allen “Duffy” Samuels, founder and chief executive officer of the nonprofit Duffy’s Hope. “Students will have the opportunity to see colleges and universities in other states. For many of them, this is the first time they’ve left Delaware.”
Born and raised in Wilmington, Samuels graduated from Glasgow High School and attended a junior college in Maryland. Two years later, he continued his higher education with the help of a basketball scholarship. Using his abilities as a top performing basketball player, Samuels joined a professional team in Europe. After touring for six years, he came back to his roots and made a commitment to help Delaware flourish.
“The Duffy’s Hope college tour offers a fun and engaging way for students to explore their options,” said Patricia Nash Christel, vice president, Navient. “We’re proud to support these young people, many of whom will be the first in their family to pursue post-secondary education, on their journey to succeed in college and a future career.”
The annual tour had its beginnings in the spring of 2013. This year, 15 students will participate in the college tour including 13 from Wilmington. The tour will begin on April 2 through April 6. Students will also visit universities in Delaware at the end of April.
Supporting adolescents ages 12-17, Duffy’s Hope uses a holistic approach to determine and rectify root causes in the lives of at-risk youth. Key issues are addressed using a 10-step program, including mentorship, parent and family involvement, experiential learning, financial literacy and etiquette training.
Connect with @Navient on Facebook, Twitter, LinkedIn and Medium.
About Navient
Navient (Nasdaq:NAVI) is a leading provider of asset management and business processing solutions for education, healthcare, and government clients at the federal, state, and local levels. The company helps its clients and millions of Americans achieve financial success through services and support. Headquartered in Wilmington, Delaware, Navient employs team members in western New York, northeastern Pennsylvania, Indiana, Tennessee, Texas, Virginia, Wisconsin and other locations. Learn more at navient.com
Contact
Brianna Huff, 302-283-2973, [email protected]
NAVICP
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/be6ad652-0ca9-44bb-984a-9c36e816a429.


Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Washington Post Publisher Will Lewis Steps Down After Layoffs
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 



